Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

BACKGROUND: CGM097 inhibits the p53-HDM2 interaction leading to downstream p53 activation. Preclinical in vivo studies support clinical exploration while providing preliminary evidence for dosing regimens. This first-in-human phase I study aimed at assessing the safety, MTD, PK/PD and preliminary an...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Sebastian, Demetri, George D., Halilovic, Ensar, Dummer, Reinhard, Meille, Christophe, Tan, Daniel S. W., Guerreiro, Nelson, Jullion, Astrid, Ferretti, Stephane, Jeay, Sebastien, Van Bree, Laurence, Hourcade-Potelleret, Florence, Wuerthner, Jens U., Fabre, Claire, Cassier, Philippe A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405607/
https://www.ncbi.nlm.nih.gov/pubmed/34140638
http://dx.doi.org/10.1038/s41416-021-01444-4

Ejemplares similares

Ejemplares similares